BWAY
Brainsway Ltd
NASDAQ: BWAY · HEALTHCARE · MEDICAL DEVICES
$16.74
-2.66% today
Updated 2026-06-05
Market cap
$572.12M
P/E ratio
64.86
P/S ratio
10.18x
EPS (TTM)
$0.22
Dividend yield
—
52W range
$5 – $17
Volume
0.1M
WallStSmart proprietary scores
49
out of 100
Grade: C
Sell
Investment rating
10.0
Growth
A+7.5
Quality
B+6.5
Profitability
B4.0
Valuation
C5/9
Piotroski F-Score
Moderate
1.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$16.67
-0.42%
12-Month target
$6.75
-59.68%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy3 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $402000.00 — positive
+ Revenue growth 34.60% QoQ
+ Debt/equity 0.09x — low leverage
Risks
- Altman Z 1.40 — distress zone
- P/E 64.86x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $27.18M | $31.79M | $41.02M | $52.23M | $56.22M |
| Net income | $-13.35M | $-4.20M | $2.92M | $7.63M | $2.29M |
| EPS | — | — | — | — | $0.22 |
| Free cash flow | $-11.70M | $-1.10M | $6.50M | $16.40M | $402000.00 |
| Profit margin | -49.12% | -13.20% | 7.12% | 14.62% | 15.60% |
Peer comparison
Smart narrative
Brainsway Ltd trades at $16.74. representing a P/E of 64.86x trailing earnings. Our Smart Value Score of 49/100 indicates the stock is fair. The company scores 5/9 on the Piotroski F-Score. With an Altman Z-Score of 1.40, it sits in the distress. TTM revenue stands at $56.22M. with profit margins at 15.60%.
Frequently asked questions
What is Brainsway Ltd's stock price?
Brainsway Ltd (BWAY) trades at $16.74, on a P/E of 64.9x and a P/S of 10.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Brainsway Ltd overvalued?
Brainsway Ltd carries a Smart Value Score of 49/100 (Grade C), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Brainsway Ltd (BWAY)?
The 12-month analyst consensus target is $16.67, about 0.4% below the current $16.74. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of BWAY by 2030?
Our research-backed model puts the 2030 base case at $9.55, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Brainsway Ltd's revenue?
Brainsway Ltd's trailing twelve-month revenue is $56.22M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Brainsway Ltd's Altman Z-Score is 1.40, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.18x
ROE11.63%
Beta0.22
50D MA$15.14
200D MA$10.94
Shares out0.04B
Float0.03B
Short ratio—
Avg volume0.1M
Performance
1 week+0.00%
1 month-14.84%
3 months+1.31%
YTD-26.97%
1 year—
3 years—
5 years—